HCC is the third most common cause of cancer-related deaths worldwide and has a poor clinical outcome 1 . Similarly to other solid tumors, HCC development is believed to be a multistep process with accumulation of genetic and epigenetic alterations 2,3 , but because of technical limitations, many of these have not been well defined. The recent advent of genomic tools, including RNA sequencing (RNA-Seq), has provided powerful methods to identify on a global level changes in transcriptomes and genomes to understand cancers at the molecular level [4] [5] [6] .
HCC is the third most common cause of cancer-related deaths worldwide and has a poor clinical outcome 1 . Similarly to other solid tumors, HCC development is believed to be a multistep process with accumulation of genetic and epigenetic alterations 2,3 , but because of technical limitations, many of these have not been well defined. The recent advent of genomic tools, including RNA sequencing (RNA-Seq), has provided powerful methods to identify on a global level changes in transcriptomes and genomes to understand cancers at the molecular level [4] [5] [6] .
In this study we performed an integrative RNA-Seq analysis on three pairs of HCC tissues and their matched nontumor tissue counterparts and identified an A→I RNA editing event involved in HCC progression. In humans, the most frequent type of RNA editing is conversion of adenosine to inosine, with the splicing and translational machineries subsequently recognizing the inosine as a guanosine. We found that A→I RNA editing occurs at residue 367 of AZIN1, resulting in a serine-to-glycine (Ser→Gly) amino acid substitution. Moreover, approximately 50% of primary HCC samples showed AZIN1 overediting. A→I (G) editing is mediated by the double-stranded RNAspecific adenosine deaminase acting on RNA (ADAR) family 7 . In this study we demonstrate that ADAR1-mediated AZIN1 RNA editing is linked to tumor initiation and development. Supplementary Fig. 1a-c ) . We performed a validation analysis for ten of the intersecting cSNVs (all are nonsynonymous substitutions) and confirmed eight out of ten variations (Supplementary Data and Supplementary Fig. 1d,e) . Through genotyping validation of the DNA samples, we found that AZIN1 had a high frequency of nonsynonymous A→I transcript editing, leading to a Ser→Gly amino acid substitution (Supplementary Data and Supplementary Fig. 1f-h ). We detected A→I (G) editing of Azin1 in mouse (Mus musculus) liver tissue, suggesting that the AZIN1 editing site is evolutionarily conserved and the sequence encompassing RNA secondary structure should also be conserved. We found that a 100-bp region in intron 11 immediately downstream of exon 11 is conserved, especially within the first 16 bp (100% identity). For siteselective A→I editing within protein-coding regions, an imperfect fold-back double-strand RNA (dsRNA) structure is formed between complementary edited exonic and downstream intronic complementary sequence termed the editing-site complementary sequence 8 . We hypothesized that the AZIN1 transcript undergoes A→I editing by a similar mechanism involving the fold-back dsRNA structure that occurring in GluR-B (also known as GRIA2) transcripts 9, 10 . The RNA secondary structure may juxtapose the AZIN1 editing site and the potential editing-site complementary sequence for A→I conversion (Supplementary Data and Supplementary Fig. 2 ). a r t i c l e s 2 1 0 VOLUME 19 | NUMBER 2 | FEBRUARY 2013 nature medicine
We investigated AZIN1 editing in 135 matched primary HCC and nontumor liver tissues from a cohort of individuals from Guangzhou, China (the GZ cohort), as well as in 46 matched primary HCC and nontumor liver samples from a cohort of individuals from Shanghai, China (the SH cohort). Approximately 46.7% (63/135 patients in the GZ cohort) and 50.0% (23/46 patients in the SH cohort) of the primary HCC specimens had AZIN1 overediting, defined by an increase of not less than 10% editing in tumors compared to in adjacent nontumor specimens (Fig. 1a) .
We found AZIN1 editing to be significantly higher in healthy liver tissues than in peripheral blood mononuclear cells (PBMCs) (P = 0.0007) and other normal tissues (Fig. 1b and Supplementary  Fig. 3) . Notably, the degree of AZIN1 editing gradually increased during HCC pathogenesis from normal to adjacent nontumor to clinically verified HCC (Fig. 1b) . Patients with HCC with liver cirrhosis had a higher frequency of AZIN1 editing than patients without liver cirrhosis (37.13% compared to 28.93%, respectively, P = 0.0052), and this frequency was also higher in patients with HCC with tumor recurrence than in patients without tumor recurrence (36.99% compared to 31.12%, respectively, P = 0.012; Fig. 1b) . Clinicopathological analyses demonstrated that AZIN1 overediting in tumors was significantly correlated with liver cirrhosis (P = 0.003), tumor recurrence (P = 0.001) and worse prognoses (P disease free = 0.008) (Fig. 1c-e and Supplementary Tables 5 and 6). In summary, AZIN1 editing frequency increases during progression from cirrhosis and primary liver cancer to advanced HCC with recurrence and metastasis.
ADAR1 is responsible for AZIN1 RNA editing in human cancers On the basis of our RNA-Seq analysis, the two ADAR1 transcript variants (NM_001025107 and NM_015840), encoding 110-kDa (p110) and 150-kDa (p150) isoforms, respectively, had relatively high abundances in liver tissue. Other ADAR family members had either extremely low (ADAR2) or undetectable (ADAR3) expression (Supplementary Fig. 4a -c).
We further examined the expression of ADAR1-ADAR3 in clinical specimens of 94 patients with HCC from the GZ cohort. We could not detect ADAR3 in any of the samples, and the expression of ADAR1 was 32-fold higher than that of ADAR2 in the human liver samples (Supplementary Fig. 4d ). Both the p110 and p150 isoforms of ADAR1 were upregulated in 83% (25/30) of the patients with HCC, and the p110 isoform was more highly upregulated than p150 (Fig. 2a) . AZIN1 editing frequency was positively correlated with the expression of ADAR1 but not ADAR2 (Fig. 2b,c) . To investigate the role of ADAR1 in the AZIN1 editing regulation during cancer development, we also determined the editing of AZIN1 and expression of ADAR1 in two other types of human cancers, esophageal squamous cell carcinoma (ESCC) and nasopharyngeal carcinoma (NPC). Similar to in HCC, the editing and expression of ADAR1 in tumor specimens of 43 patients with ESCC from Queen Mary Hospital (Hong Kong, China) were significantly higher than in adjacent nontumor tissues (P < 0.0001; Fig. 2d ), which may be explained by the higher ADAR1 expression (as shown by a lower ∆Ct value) in the HCC and ESCC tumor samples compared with the matched nontumor tissues (Fig. 2e) . We found no clear differences in AZIN1 editing or ADAR1 expression between the tumor and nontumor specimens of 33 patients with NPC from Queen Mary Hospital (Hong Kong, China) (Fig. 2d,e) . These data suggest that ADAR1 has a major role in A→I (G) AZIN1 editing during cancer development.
The editing of pre-mRNA is often restricted to the nucleus, particularly for editing events involving a fold-back dsRNA structure 11 . Because of its regulation by interferon (IFN) and cytoplasmic localization, the ADAR1 p150 isoform is presumably responsible for the A→I editing of viral RNAs produced by viruses 7, 12 but not of nuclear premRNAs 11 . By contrast, the nuclear ADAR1 p110 isoform and ADAR2 are expressed constitutively. Therefore, we investigated whether the ADAR1 p110 isoform or ADAR2 is responsible for A→I editing of the AZIN1 pre-mRNA. Overexpression of ADAR1 p110 but not ADAR2 led to a fivefold increase in AZIN1 editing ( Fig. 2f-h ).
Silencing ADAR1 in the HCC cell line H2M markedly decreased AZIN1 editing and was rescued by overexpressing an ADAR1 p110 mutant that preserves the native amino acid sequence but contains six point mutations within the ADAR1 shRNA targeting sequence (Fig. 2i,j) . In summary, studies of the expression of ADAR family members and functional studies support the notion that the ADAR1 p110 isoform induces AZIN1 overediting.
AZIN1 A→I (G) editing induces a tumorigenic phenotype
To ascertain whether there is a causative relationship between RNA editing and gain-of-function phenotypes in cancer development, we introduced V5-tagged wild-type AZIN1 (wt/AZI) or edited AZIN1 (edt/AZI) expression constructs into two HCC cell lines (PLC8024 and QGY-7703). Cells transduced with the edt/AZI lentivirus (804-edt/AZI and 7703-edt/AZI) with 84-90% of their AZIN1 transcripts edited (Supplementary Fig. 5a,b ) had accelerated growth rates and higher frequencies of focus and colony formation in soft agar than cells transduced with the wt/AZI (8024-wt/AZI and 7703-wt/AZI) or control LacZ lentivirus (8024-LacZ and 7703-LacZ) (Fig. 3a-c) .
Consistent with the clinical correlation between AZIN1 overediting and tumor recurrence, 8024-edt/AZI and 7703-edt/AZI cells had increased invasive capability (Fig. 3d) .
To analyze whether the gain-of-function phenotypes are regulated in an edited AZIN1-dependent manner, we compared the tumorigenic properties of the wt/AZI transfectant (8024-Wt1) with three edt/AZI transfectants (8024-Edt1, 8024-Edt2 and 8024-Edt3) with different AZIN1 editing frequencies (24.8%, 42.9% and 85.3%, respectively). 8024-Edt3 cells, harboring 85.3% edited AZIN1 transcripts, showed the most aggressive phenotype (Fig. 3e-h) . As little as an 18% increase in AZIN1 editing (8024-Edt1 compared to 8024-Edt2 cells) was sufficient to promote tumorigenic potential (Fig. 3e-h ). These data demonstrate that tumorigenic properties correlate with AZIN1 editing.
Xenograft studies in mice demonstrated that the incidence of tumors derived from 8024-edt/AZI cells was markedly higher than those derived from 8024-wt/AZI and 8024-LacZ cells (Fig. 4a,b) . Moreover, 70% of mice injected with 8024-edt/AZI cells formed tumors within 1 week; however, none of the mice injected with 8024-LacZ cells and only 10% of the mice injected with 8024-wt/AZI cells had visible tumors after 4 weeks (Fig. 4a,b) . Tumors induced by 8024-edt/AZI cells grew significantly faster than those induced by 8024-LacZ or 8024-wt/AZI cells (Fig. 4c) . Furthermore, 4 weeks after intrahepatic inoculation, mice injected with 8024-edt/AZI cells formed more liver nodules (Fig. 4d-f) . All these data demonstrate that this recoding editing has an important role in tumor initiation.
AZIN1 editing causes a cytoplasmic-to-nuclear translocation Editing of AZIN1 results in an amino acid change (Ser→Gly) at residue 367. GFP-tagged wild-type AZIN1 protein (GFP-wt/AZI) was predominantly expressed in the cytoplasm, whereas the majority of the edited protein (GFP-edt/AZI) was expressed in the nucleus of PLC8024 and QGY-7703 cells (Fig. 5a) . We found that the centrosomal localization of wild-type AZIN1 protein was consistent with observations reported previously 13 (Fig. 5a) . Despite equal amounts of GFP-wt/AZI and GFP-edt/AZI in whole-cell lysates, the amount of cytoplasmic GFP-wt/AZI protein was fourfold higher than that of cytoplasmic GFP-edt/AZI protein, whereas edited AZIN1 protein was fourfold more abundant in the nuclei than in the cytoplasm, indicating that the AZIN1 editing may result in a cytoplasmicto-nuclear translocation (Fig. 5b) . By immunohistochemistry (IHC), we found cytoplasmic-to-nuclear translocation of AZIN1 in 5/14 (35.7%) patients with HCC with AZIN1 overediting (Fig. 5c) .
We hypothesized that this translocation might be caused by a conformational change as a result of the Ser→Gly substitution at 14 identified two individual switching elements (switch 1, residues 362-367, and switch 2, residues 385-394) from the 448-amino-acid protein sequence (Fig. 5d) , suggesting that the amino acid change within these two elements could be involved in the conformational change in AZIN1. Interestingly, Ser367 is located at the switch 1 region, suggesting that a Ser→Gly substitution at residue 367 might have the potential to induce a conformational change in AZIN1.
Edited AZIN1 inhibits antizyme degradation function Antizyme (also named antizyme-1) inhibits cell growth by binding to and inducing degradation of proteins such as ODC. AZIN1 is an ODC homolog and shares its capacity to bind to antizyme, but AZIN1 binds to antizyme with a higher affinity than does ODC 15 . We then investigated whether AZIN1 editing could affect the binding affinity of AZIN1 protein to antizyme. Compared to PLC8024 cells transfected with GFP-wt/AZI, more antizyme-1 protein could be pulled down by a GFP-specific antibody from the lysates of cells transfected with GFP-edt/AZI (Fig. 6a) .
We found that more antizyme-1 protein could be immunoprecipitated in 8024-edt/AZI cells than in 8024-wt/AZI cells using a V5-specific antibody (Supplementary Fig. 6a) . Furthermore, an equal amount of recombinant maltose-binding protein (MBP)-fused antizyme-1 (MBP-OAZ1) could pull down more GFP-edt/AZI than GFP-wt/AZI protein (Fig. 6b) . All of these data indicate that the edited AZIN1 had a higher binding affinity to antizyme-1 than did wild-type AZIN1. As a consequence of its increased binding affinity to antizyme, edited AZIN1 protein was more stable than wild-type AZIN1 (Fig. 6c,d and Supplementary Fig. 6b-d) , consistent with previous findings that the AZIN1-antizyme interaction prevents AZIN1 from undergoing ubiquitin-mediated degradation 16 .
Binding of AZIN1 inhibits antizyme-mediated binding and degradation of the ODC and cyclin D1 (CCND1) oncoproteins [17] [18] [19] . Degradation of ODC and CCND1 was attenuated in cells expressing GFP-or V5-tagged edited AZIN1 compared with cells expressing wild-type AZIN1 (Fig. 6c,d and Supplementary Fig. 6b-d) . Therefore, AZIN1 editing confers greater stability to the AZIN1 protein as a result of the higher affinity of the edited form toward antizyme compared to the wild-type form, inducing malignant transformation by neutralizing antizyme-mediated degradation of downstream oncoproteins.
A functional edt/AZI-ODC-CCND1 cell proliferation axis The promotion of cell proliferation is a major mechanism associated with the transformation of a normal cell to a cancer cell 20 , and ODC and CCND1 are two key factors in regulation of the G1/S phase transition. Elevated ODC and CCND1 expression at the G1/S boundary lead to the augmentation of protein synthesis that is necessary for entry into the cell cycle 21, 22 .
We isolated tumorigenic cells from xenografts derived from 8024-wt/AZI and 8024-edt/AZI cells (xeno-wt/AZI and xeno-edt/AZI) and measured the G1/S transition and cell proliferation using BrdU incorporation. Xeno-edt/AZI cells had a 13-fold higher AZIN1 editing frequency and entered S phase faster than xeno-wt/AZI cells (Supplementary Fig. 7a,b) . The percentage of xeno-edt/AZI cells in S phase was consistently higher than that of xeno-wt/AZI cells at 6 h and 9 h after release (Fig. 6e) . At the G1/S boundary, phosphorylation of the retinoblastoma protein (Rb) activates the E2F transcription factor and downstream targets such as cyclin A (CCNA), Cdc2 and c-Myc 23 . Compared with xeno-wt/AZI cells, xeno-edt/AZI cells had elevated expression of ODC and CCND1, leading to increased Rb phosphorylation and subsequent upregulation of CCNA (Fig. 6f,g) . from 8024-edt/AZI cells showed cytoplasmic-to-nuclear translocation of AZIN1 and higher expression of ODC, CCND1 and the proliferation marker Ki-67 than tumors derived from 8024-wt/AZI cells (Supplementary Fig. 7c ). These data suggest that there is a tight connection between the edt/AZI-ODC or -CCND1 cell proliferation axis and tumor initiation and progression.
DISCUSSION
RNA editing is defined as post-transcriptional alteration of RNA sequences and is an additional epigenetic control mechanism [24] [25] [26] .
Until recently, only a small number of proteins with amino acid substitutions caused by editing were known, and it seems that many of the newly identified recoding events have low-level modification rates and low validity 27, 28 . In this study, RNA editing of AZIN1 showed a relatively higher modification ratio, and we detected the accumulation of a S367G substitution in tumor specimens, particularly HCCs. AZIN1 protein is originally found in rat liver extract 15 , which may assume its physiological importance in the context of liver tissue. In this study we found that the AZIN1 editing was higher in healthy liver tissues than in PBMCs and other normal tissues, confirming that the RNA editing frequency can be regulated in a tissue-specific or cell type-specific manner, which is consistent with observations reported previously 9 . In contrast with the notion that hypoediting is associated with several cancer phenotypes [29] [30] [31] , we found that AZIN1 editing increased during the multistep progression of HCC from healthy liver to HCC. Moreover, AZIN1 overediting in tumors was predictive of poor prognosis and associated with liver cirrhosis and tumor recurrence. Three members of the ADAR family (ADAR1, ADAR2 and ADAR3) have been identified to catalyze A→I RNA editing 32 . However, no substrate for ADAR3 has been identified so far. We showed that RNA editing of AZIN1 was specifically regulated by ADAR1 but not ADAR2 or ADAR3. Moreover, we found AZIN1 RNA editing to be conserved, implying that the cis-acting sequences necessary for RNA editing should also be conserved. Computer programs that predict RNA secondary structures aligned the highly conserved exonic sequence with the intronic sequence immediately downstream of the edited exon within a highly base-paired doublestranded RNA secondary structure. A series of assays in both cell culture and xenografts provided direct evidence that edited AZIN1 protein confers gain-of-function phenotypes manifested by higher proliferative rate, greater invasive ability and higher incidence of tumor formation. Notably, we found that an 18% increase in AZIN1 editing was sufficient to promote the tumorigenic potentials of HCC cells. All of these findings suggest that overediting contributes to cancer initiation and progression. Editing of AZIN1 induced cytoplasmic-to-nuclear translocation in HCC cells and clinical samples. Recent crystallographic and biochemical analysis of the mouse antizyme inhibitor (mAzI) revealed substantial conformational differences between the structures of mAzI and Odc in the two loops positioned at the dimer interface (loop 1, residues 355-362, and loop 2, residues 387-401) 33 , suggesting that these loop regions at the surface of the mAzI protein are crucial for maintaining its specific conformation. We identified two individual switching elements (switch 1, residues 362 -367, and switch 2, residues 385-394) in AZIN1. We found that the predicted AZIN1 switch 2 maps to loop 2, whereas the switch 1 element (residues 362-367), mapping to β15, is located adjacent to loop 1. These data suggest that S367G editing within switch 1 may induce a conformational change in AZIN1. Because a small percentage of wild-type AZIN1 protein localizes to the nucleus, the mechanism underlying the cytoplasmicto-nuclear translocation probably does not depend solely on editing. This may explain why the AZIN1 cytoplasmic-to-nuclear change in tumor samples was not observed as frequently as overediting.
Antizyme is the first known mammalian protein whose synthesis is characterized by ribosomal frame shifting 34, 35 , and it regulates cell growth by binding to and inducing degradation of growth-promoting proteins such as ODC and CCND1. In addition, the antizyme-ODC interaction leads to a conformational alteration of ODC, thereby inducing a ubiquitin-independent proteasomal degradation of ODC 16, 36 . The antizyme inhibitor AZIN1 is an ODC homolog that binds to antizyme with greater affinity than does ODC 15 . The ability of antizyme to degrade ODC, inhibit polyamine uptake and, consequently, suppress cellular proliferation suggests it is a tumorsuppressor gene. In contrast, AZIN1 prevents proteolytic degradation of ODC by sequestering antizyme from ODC. Therefore, AZIN1 acts as an oncogene by inhibiting the tumor-suppressor activities of antizyme. Consistent with this model, accumulating evidence suggests that an elevated ratio of AZIN1 to antizyme favors growth activation. Moreover, AZIN1 expression was found to be substantially elevated in cancers of the prostate, brain, breast and liver, and gene expression data have identified alterations in the AZIN1-to-antizyme ratio in many human cancers 37 . In this study we describe a third unusual mechanism of regulation of the antizyme-AZIN1 axis: AZIN1 RNA editing. RNA editing of AZIN1 confers greater antizyme binding, leading to inhibition of degradation of the target oncoproteins ODC and CCND1 and facilitating entry into the cell cycle 21, 22 .
Collectively, the A→I (G) RNA editing that occurs at residue 367 (Ser→Gly) of the AZIN1 gene, which is specifically catalyzed by ADAR1, is more abundant in tumor specimens. This recoding editing event is predicted to affect protein conformation, leading to changes in subcellular localization and function. Edited AZIN1, with a stronger affinity toward antizyme and a resultant higher protein stability than wild-type AZIN1, promotes cell proliferation and tumor progression by neutralizing the antizyme-mediated degradation of the ODC and CCND1 oncoproteins. Thus, HCC tumors have increased A→I (G) AZIN1 editing, leading to inhibition of antizyme tumorsuppressor function, providing a gain-of-function event driving HCC pathogenesis.
METHODS
Methods and any associated references are available in the online version of the paper.
